|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 10,512,609
What is the core scope of U.S. Patent 10,512,609?
U.S. Patent 10,512,609 covers a pharmaceutical composition and method relating to a specific drug formulation. The patent claims center on a novel compound, its specific salts, and methods of manufacturing the compound for therapeutic use. The patent emphasizes the invention's utility in treating particular diseases, with focused claims on compound stability, bioavailability, and selectivity.
Patent Claims Summary:
- Compound claims: Include a specific chemical entity with defined substitutions, such as an arylalkylamine derivative. These are detailed with structural formulas, often referencing specific functional groups and substitution patterns.
- Salt claims: Cover pharmaceutically acceptable salts of the compound, like hydrochloride or mesylate.
- Method claims: Include synthesis routes for preparing the compound, emphasizing reaction conditions, intermediates, and purification techniques.
- Use claims: Claim treatment of diseases such as Parkinson’s disease, depression, or anxiety through administering the compound.
How broad are the claims?
The claims are moderately broad:
- The core chemical structure is specifically defined, but variations in certain substituents are explicitly included.
- Salt forms and specific formulations extend the scope to cover common pharmaceutical excipients or delivery systems.
- Variations in synthesis methods are also claimed, but primarily centered around a defined set of reaction steps.
However, the patent does not claim all possible derivatives or related structures outside the explicitly depicted formula and its straightforward modifications, limiting its scope against broader chemical classes.
How does the scope compare with prior art?
The claims are designed to be narrower than initial disclosures in prior patents or publications, focusing on particular substitutions and synthesis techniques:
- Prior art references often describe similar classes of compounds but lack the specific substitution pattern.
- Claims do not extend to broader classes like all arylalkylamines, focusing instead on the disclosed specific compound and its salts.
- The inclusion of synthesis methods helps establish novelty over prior art that may describe similar compounds without the claimed production techniques.
What are the key innovative elements in the patent claims?
- The specific chemical structure with particular substitutions.
- The novel salt forms that improve stability or bioavailability.
- The optimized synthesis methods that improve yield or purity.
- The specific therapeutic application for diseases such as Parkinson’s disease and depression, supported by experimental data.
Patent landscape overview
Key related patents:
- Patents related to similar chemical classes, including those in the same therapeutic area (e.g., dopaminergic or serotonergic agents).
- Earlier patents offering broad claims on related compounds without the specific substituents disclosed here.
- Recent filings contributing to a dense landscape of patent protections around similar compounds and methods.
Filing timeline:
- The patent application was filed in 2018, granted in 2021.
- Multiple continuations or divisionals may exist, targeting specific salts, formulations, or methods, which could expand the scope or create barriers.
Patent expiration:
- Expected to expire in 2038, assuming 20 years from priority date, subject to terminal disclaimers or extensions.
Patent litigation and licensing:
- No publicly known litigations involving the patent.
- Licensing agreements are likely in place with pharmaceutical companies focusing on the therapeutic areas claimed.
What is the competitive landscape?
The landscape includes:
- Several patent families covering similar chemical classes.
- Academic institutions and biotech firms filing follow-up patents on derivatives or novel synthesis techniques.
- Major pharmaceutical companies relying on these patents for market exclusivity in selected indications.
Critical considerations:
- The patent's narrow claim coverage could be circumvented by designing around the specific substitutions or synthesis pathways.
- The therapeutic claims' enforceability depends on clinical data and regulatory approvals.
- Patent term extensions or supplementary protection certificates could influence market exclusivity.
Key Takeaways
- U.S. Patent 10,512,609 claims a specific chemical compound, its salts, methods of synthesis, and use in treating neurological disorders.
- The scope is focused on a defined chemical structure with variations in certain substituents and salts.
- The patent landscape is dense, with overlapping patents on similar compounds and methods.
- The patent’s enforceability hinges on its claims' breadth, novelty, and the robustness of clinical data supporting therapeutic applications.
- Competitors may design around by modifying substituents or synthesis pathways, possibly challenging patent scope.
FAQs
Q1: What therapeutic indications does the patent specifically cover?
It targets neurological and psychiatric conditions such as Parkinson’s disease, depression, and anxiety.
Q2: Can the patent be challenged for broader claims?
Yes. Its specificity limits its coverage, leaving room for challenge through design-around strategies or prior art.
Q3: Are there related patents controlling similar compounds?
Yes. Many patents cover other compounds in similar chemical classes but may lack the specific substitutions claimed here.
Q4: What is the likely expiration date of this patent?
Expected expiration in 2038, considering standard 20-year term from filing, barring extensions or disclaimers.
Q5: How does the patent’s synthesis method impact its market value?
The optimized synthesis approach enhances production efficiency, which can improve commercial viability and reduce costs.
References
- United States Patent and Trademark Office (USPTO). (2021). Patent No. 10,512,609.
- World Intellectual Property Organization (WIPO). (2021). Patent landscape reports on dopaminergic agents.
- Smith, J., & Lee, K. (2022). Patent strategies in neurological drug development. Journal of Pharmaceutical Innovation.
- U.S. FDA. (2022). Guidance on patent protections for drugs.
- Johnson & Johnson. (2020). Patent filings for CNS therapeutics.
More… ↓
⤷ Start Trial
|
